8-K: Annexon's ANX007 Shows Enhanced Vision Protection in Dry AMD Patients with Less Advanced Disease

Annexon's ANX007 demonstrated enhanced vision protection and greater preservation of photoreceptor cells in a subpopulation of dry age-related macular degeneration patients with less advanced disease in a Phase 2 study.

Summary

• Annexon announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD).
• ANX007 showed enhanced protection of vision and greater preservation of central photoreceptor cells in a subpopulation of patients with less advanced disease.
• The data were presented at the American Academy of Ophthalmology (AAO) 2024 annual meeting.
• ANX007 is designed to block C1q locally in the eye, which is a key driver of neurodegeneration in dry AMD.
• The study showed that ANX007 provided significant protection from vision loss, particularly in patients with less advanced disease.
• In a subpopulation with less advanced disease, 0% of ANX007 treated patients lost 15 letters on an eye chart compared to 17% of sham patients.
• ANX007 also showed a 61% decrease in EZ loss compared to sham in patients with less than 80% EZ loss at baseline.
• The company expects pivotal Phase 3 ARCHER II data in the second half of 2026.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results for ANX007, showing significant improvements in vision protection and photoreceptor preservation, particularly in a subpopulation of patients. The company also has a clear path forward with Phase 3 trials planned. However, there are risks associated with the company's financial position and the early stage of development.

Positives

• ANX007 showed a significant treatment effect on both preservation of vision and photoreceptors, particularly in patients with less advanced disease.
• The treatment effect of ANX007 increased over the course of the study, suggesting a growing and durable effect over time.
• ANX007 was shown to protect key retinal structures important for vision.
• The drug has received Fast Track designation from the FDA and Priority Medicine (PRIME) designation in the EU.

Negatives

• The rate of decline for BCVA 15-letter vision after treatment termination began to parallel that of sham, suggesting the treatment effect may not be permanent.

Risks

• The company has a history of net operating losses.
• The company's ability to obtain necessary capital to fund its clinical programs is a risk.
• The clinical development of the company's product candidates is in early stages.
• There are risks associated with obtaining regulatory approval and successfully commercializing product candidates.
• Undesirable side effects or other properties of the company's product candidates are a risk.
• The company relies on third-party suppliers and manufacturers.
• The company's ability to adequately maintain intellectual property rights for its product candidates is a risk.

Future Outlook

The company anticipates pivotal Phase 3 ARCHER II data in the second half of 2026, and is focused on advancing ANX007 as a potential treatment for dry AMD and GA.

Management Comments

• Douglas Love, president and chief executive officer of Annexon, stated that they are encouraged by ANX007's consistent and robust effect on the structural elements of the eye.
• He also noted that they are further encouraged by ANX007's more pronounced treatment effect on both preservation of vision and photoreceptors in patients with less advanced disease.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for dry AMD and GA, which currently have no approved therapies that significantly prevent vision loss. The results suggest that ANX007 could be a differentiated treatment option, particularly with earlier intervention.

Comparison to Industry Standards

• Currently, there are no approved therapies that have been shown in clinical trials to significantly prevent vision loss in dry AMD and GA.
• The results of the ANX007 trial are being compared to the sham group in the same trial, and the results are showing a significant improvement in vision loss and photoreceptor preservation.
• Other companies are also developing treatments for dry AMD and GA, including gene therapies and complement inhibitors, but ANX007's approach of targeting C1q is unique.

Stakeholder Impact

• The positive results could be beneficial for shareholders, as they indicate potential for a successful product.
• The results are also positive for patients with dry AMD and GA, as they suggest a potential new treatment option.
• The company's employees may also be positively impacted by the progress of the clinical trial.

Next Steps

• The company will continue the off-treatment follow-up portion of the Phase 2 ARCHER trial.
• The company is planning for the pivotal Phase 3 ARCHER II trial, with data expected in the second half of 2026.

Key Dates

Keywords

ANX007, geographic atrophy, dry AMD, age-related macular degeneration, vision loss, photoreceptor, C1q, neurodegeneration, clinical trial, ophthalmology